Suggested remit: To appraise the clinical and cost effectiveness of tirzepatide within its marketing authorisation for managing obesity or overweight with risk factors.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6179

Provisional Schedule

Committee meeting: 3 13 August 2024
Expected publication 30 October 2024

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick


Companies sponsors Eli Lilly and Company
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
  Welsh Government
Patient carer groups All About Obesity
  Diabetes UK
  Obesity UK
Professional groups Association for the Study of Obesity
  British Obesity and Metabolic Surgery Society
  Royal College of General Practitioners
  Royal College of Physicians
Comparator companies NovoNordisk
General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
04 June 2024 - 25 June 2024 Draft guidance
09 April 2024 Committee meeting: 2
06 March 2024 The next appraisal committee meeting will now take place on 9 April 2024.
08 February 2024 The appraisal was discussed by the technology appraisal committee on 16 January 2024. The committee requires further information before it can make a recommendation on tirzepatide for obesity. We have requested this information from stakeholders and the committee will reconsider this topic at its meeting on 12 March 2024.
16 January 2024 Committee meeting: 1
13 June 2023 Invitation to participate
26 May 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
23 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Tirzepatide for managing overweight and obesity have been revised. It is anticipated that the appraisal will begin in mid-May 2023 when we will write to you about how you can get involved.
24 January 2023 - 21 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2023 In progress. Scoping commenced
17 October 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual